Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial - PubMed (original) (raw)
Clinical Trial
. 2006 Jun 21;295(23):2742-51.
doi: 10.1001/jama.295.23.joc60075. Epub 2006 Jun 5.
D Lawrence Wickerham, Joseph P Costantino, Marcie W Ritter, Victor G Vogel, Myoungkeun Lee, Eduardo R Pajon, James L Wade 3rd, Shaker Dakhil, James B Lockhart Jr, Norman Wolmark, Patricia A Ganz
Affiliations
- PMID: 16754728
- DOI: 10.1001/jama.295.23.joc60075
Clinical Trial
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
Stephanie R Land et al. JAMA. 2006.
Erratum in
- JAMA. 2007 Sep 5;298(9):973
Abstract
Context: Tamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with tamoxifen is unknown.
Objective: To compare the differences in patient-reported outcomes, quality of life [QOL], and symptoms in Study of Tamoxifen and Raloxifene (STAR) participants by treatment assignment.
Design, setting, participants, and interventions: STAR was a double-blind, randomized phase 3 prevention trial designed to evaluate the relative efficacy of raloxifene vs tamoxifen in reducing the incidence of invasive breast cancer in high-risk postmenopausal women. Between July 1, 1999, and November 4, 2004, 19,747 participants were enrolled at centers throughout North America, with a median potential follow-up time of 4.6 years (range, 1.2-6.5 years). Patient-reported symptoms were collected from all participants using a 36-item symptom checklist. Quality of life was measured with the Medical Outcomes Study Short-Form Health Survey (SF-36), the Center for Epidemiologic Studies-Depression (CES-D), and the Medical Outcomes Study Sexual Activity Questionnaire in a substudy of 1983 participants, median potential follow-up 5.4 years (range, 4.6-6.0 years). Questionnaires were administered before treatment, every 6 months for 60 months and at 72 months.
Main outcome measures: Primary QOL end points were the SF-36 physical (PCS) and mental (MCS) component summaries.
Results: Among women in the QOL analysis, mean PCS, MCS, and CES-D scores worsened modestly over the study's 60 months, with no significant difference between the tamoxifen (n = 973) and raloxifene (n = 1010) groups (P>.2). Sexual function was slightly better for participants assigned to tamoxifen (age-adjusted repeated measure odds ratio, 1.22%; 95% CI, 1.01-1.46). Of the women in the symptom assessment analyses, the 9769 in the raloxifene group reported greater mean symptom severity over 60 months of assessments than the 9743 in the tamoxifen group for musculoskeletal problems (1.15 vs 1.10, P = .002), dyspareunia (0.78 vs 0.68, P<.001), and weight gain (0.82 vs 0.76, P<.001). Women in the tamoxifen group reported greater mean symptom severity for gynecological problems (0.29 vs 0.19, P<.001), vasomotor symptoms (0.96 vs 0.85, P<.001), leg cramps (1.10 vs 0.91, P<.001), and bladder control symptoms (0.88 vs 0.73, P<.001).
Conclusions: No significant differences existed between the tamoxifen and raloxifene groups in patient-reported outcomes for physical health, mental health, and depression, although the tamoxifen group reported better sexual function. Although mean symptom severity was low among these postmenopausal women, those in the tamoxifen group reported more gynecological problems, vasomotor symptoms, leg cramps, and bladder control problems, whereas women in the raloxifene group reported more musculoskeletal problems, dyspareunia, and weight gain.
Trial registration: clinicaltrials.gov Identifier: NCT00003906.
Comment in
- Selective estrogen receptor modulators and prevention of invasive breast cancer.
Gradishar WJ, Cella D. Gradishar WJ, et al. JAMA. 2006 Jun 21;295(23):2784-6. doi: 10.1001/jama.295.23.jed60037. Epub 2006 Jun 5. JAMA. 2006. PMID: 16754726 No abstract available.
Similar articles
- Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP). Vogel VG, et al. JAMA. 2006 Jun 21;295(23):2727-41. doi: 10.1001/jama.295.23.joc60074. Epub 2006 Jun 5. JAMA. 2006. PMID: 16754727 Clinical Trial. - Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Ganz PA, et al. Lancet. 2016 Feb 27;387(10021):857-65. doi: 10.1016/S0140-6736(15)01169-1. Epub 2015 Dec 11. Lancet. 2016. PMID: 26686960 Free PMC article. Clinical Trial. - Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project. Vogel VG, et al. Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19. Cancer Prev Res (Phila). 2010. PMID: 20404000 Free PMC article. Clinical Trial. - Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N. Vogel VG, et al. J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041. J Natl Cancer Inst Monogr. 2010. PMID: 20956826 Free PMC article. Review. - The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
Vogel VG. Vogel VG. Expert Rev Anticancer Ther. 2009 Jan;9(1):51-60. doi: 10.1586/14737140.9.1.51. Expert Rev Anticancer Ther. 2009. PMID: 19105706 Free PMC article. Review.
Cited by
- Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.
Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS; Athena Breast Health Network Investigators and Advocate Partners; Esserman LJ. Wang T, et al. NPJ Breast Cancer. 2024 Oct 14;10(1):90. doi: 10.1038/s41523-024-00681-z. NPJ Breast Cancer. 2024. PMID: 39397069 Free PMC article. - Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
Buijs SM, Koolen SLW, Mathijssen RHJ, Jager A. Buijs SM, et al. Drugs. 2024 Apr;84(4):385-401. doi: 10.1007/s40265-024-02010-x. Epub 2024 Mar 14. Drugs. 2024. PMID: 38480629 Free PMC article. Review. - Predictors of information needs among women with breast cancer receiving adjuvant therapy at Tikur Anbessa specialized hospital, Addis Ababa Ethiopia: a cross-sectional study.
Tilahun SW, Kitaw LD, Yusuf NT. Tilahun SW, et al. BMC Womens Health. 2023 Dec 8;23(1):659. doi: 10.1186/s12905-023-02805-2. BMC Womens Health. 2023. PMID: 38066595 Free PMC article. - Targeting nuclear hormone receptors for the prevention of breast cancer.
Moyer CL, Brown PH. Moyer CL, et al. Front Med (Lausanne). 2023 Jul 31;10:1200947. doi: 10.3389/fmed.2023.1200947. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37583424 Free PMC article. Review. - Validation Study on Risk-Reduction Activities after Exposure to a Personalized Breast Cancer Risk-Assessment Education Tool in High-Risk Women in the WISDOM Study.
Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS; Athena Breast Health Network Investigators and Advocate Partners; Esserman LJ. Wang T, et al. Res Sq [Preprint]. 2023 May 10:rs.3.rs-2787493. doi: 10.21203/rs.3.rs-2787493/v1. Res Sq. 2023. PMID: 37214889 Free PMC article. Updated. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical